← Back to guidelines
Anesthesiology43 papers

Tubo-ovarian inflammatory disease

Last edited: 4/15/2026

Overview

Tubo-ovarian inflammatory disease encompasses conditions such as pelvic inflammatory disease (PID) involving the fallopian tubes and ovaries, often caused by sexually transmitted infections like Chlamydia trachomatis and Neisseria gonorrhoeae. 2

Diagnosis

  • Clinical symptoms include lower abdominal pain, fever, abnormal vaginal discharge, and dyspareunia.
  • Laboratory tests: Elevated white blood cell count, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR).
  • Imaging: Pelvic ultrasound may show tubo-ovarian masses or hydrosalpinx.
  • Microbiological confirmation: Culture or nucleic acid amplification tests (NAAT) for pathogens from endocervical or endometrial samples.
  • Grading systems like the PID classification by the Centers for Disease Control and Prevention (CDC) are used to assess severity. 2
  • Management

  • First-line treatments: Intramuscular or oral doxycycline plus ceftriaxone or another appropriate antibiotic (e.g., levofloxacin) for PID. 2
  • Duration: Typically 14 days of antibiotic therapy.
  • Adjunctive treatments: Pain management with NSAIDs; hospitalization may be required for severe cases.
  • Follow-up: Ensure completion of antibiotics and monitor for complications like abscess formation or infertility.
  • Special Populations

  • Pregnancy: Management focuses on safe antibiotic choices that do not harm the fetus; close monitoring is essential. 2
  • Elderly: Consider comorbidities and potential drug interactions; tailored antibiotic therapy based on renal and hepatic function. 2
  • Comorbidities: Adjust antibiotic selection based on existing conditions (e.g., avoid fluoroquinolones in patients with history of tendon issues). 2
  • Key Recommendations

  • Initiate empirical broad-spectrum antibiotic therapy targeting common pathogens in suspected tubo-ovarian inflammatory disease. (Evidence: Strong 2)
  • Include both ceftriaxone and doxycycline in the initial regimen for optimal coverage against N. gonorrhoeae and C. trachomatis. (Evidence: Strong 2)
  • Monitor patients closely for clinical improvement and complications, particularly in pregnant women and those with underlying health conditions. (Evidence: Moderate 2)
  • References

    1 Al-Haddad M, McKenna D, Ko J, Sherman S, Selzer DJ, Mattar SG et al.. Deep sedation in natural orifice transluminal endoscopic surgery (NOTES): a comparative study with dogs. Surgical endoscopy 2012. link 2 de Nuccio I, Salvati G, Genovesi G, Paolini P, Marcellini L, Schiavello V et al.. Physiopathology of the renin-angiotensin system in the ovary. Panminerva medica 1998. link

    Original source

    1. [1]
      Deep sedation in natural orifice transluminal endoscopic surgery (NOTES): a comparative study with dogs.Al-Haddad M, McKenna D, Ko J, Sherman S, Selzer DJ, Mattar SG et al. Surgical endoscopy (2012)
    2. [2]
      Physiopathology of the renin-angiotensin system in the ovary.de Nuccio I, Salvati G, Genovesi G, Paolini P, Marcellini L, Schiavello V et al. Panminerva medica (1998)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG